Alnylam Pharmaceuticals, Inc. (ALNY) — Analysis Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has a market cap of $40.32B with year-over-year revenue growth of +65.2%. Net margin stands at 8.4%. The stock trades at a P/E ratio of 128.5.
Key Takeaways
- Revenue changed +65.2% year-over-year
- Net margin of 8.4%
- P/E ratio of 128.5
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ALNY posted revenue growth of +65.2% and trades at a P/E of 128.5.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.